ALACHUA ‒ For 19 years the Bits and Spurs Horse Club of Alachua County has held an annual fundraiser horse ride to continue the community remembrance of Dallas Osborne while helping a passionate 4-H member achieve their goals with a $500 scholarship. The fundraiser was sidelined during the COVID pandemic, but last year thanks to Addison Grosz, the event was back in action. Grosz, a current senior at Eastside High School, president of the club and the 4-H “Horseman of the Year” for the State of Florida, was instrumental in restarting the annual trail ride fundraiser. So successful was the last ride that it raised enough money for three scholarships. This year Grosz hopes to repeat that success.

4H is a nationwide organization that provides hands-on learning, to kids 8-18 to build confidence, creativity and curiosity as well as life skills such as leadership and resiliency to help them thrive today and tomorrow. Although mainly geared toward agriculture, the organization also has programs in science, healthy living and civic engagement—and provides these programs to over six million kids nationwide through a network of 100 public university sponsors and a community of 4H volunteers and professionals.

In 4H programs, kids and teens complete hands-on projects where they receive guidance from adult mentors and are encouraged to take on proactive leadership roles. 4H exist in every county in the country through in-school and after-school programs, school and community clubs and 4H camps.

A popular 4H program locally is the Bits and Spurs program that teaches horsemanship. One of the members of this program was high school student Dallas Osborne who was known for his dedication in teaching younger students and his leadership in the program.

Over 20 years ago, Osborne was tragically killed in a car accident, but his memory lives on through a scholarship program awarded to a graduating 4H high school student who is a member of the horse club and who exemplifies the traits Dallas shared. Each student applying for the scholarship is required to write an essay, with the winning student can use the scholarship for whatever post high school education they choose.

In a matter of weeks, this year the ride will happen on Feb. 4, 2023, and is open to any rider who wants to participate and help raise funds for the scholarships. Check in is slated for 9:30 a.m. at the North San Felasco Trail Head located at 13201 Progress Blvd., Alachua, FL 32615.

The first ride will start at 10 a.m. with additional rides later depending on the number of participants. Early Bird Registration for 4-H Youth Riders is $20 if signing up before Jan. 15. Regular / Day-Of registration fee is $30. Both fees cover admission, a t-shirt, raffle ticket and lunch at 12:30 p.m.

More information is available on facebook at http://www.facebook.com/bitsandspurs4H/ or by calling 352-574-3215.Advanced tickets can be purchased at Evenbrite at https://www.eventbrite.com/e/2023-dallas-osborne-trail-ride-tickets-405324936797.

#     #     #

Email rcarson@

alachuatoday.com

Collaborative lab space enables the development and growth of the next generation of life science companies in the greater Gainesville region

ALACHUA, Fla - As part of its efforts to support emerging biotechnology companies with addressing key challenges of bringing new therapies to market, Thermo Fisher Scientific today announced it has become a founding sponsor of Momentum Labs in Alachua, Fla. Momentum Labs will serve as a collaborative laboratory and office space for growing biotech businesses in the greater Gainesville region.

“From a regional and state perspective, Momentum Labs provides critical infrastructure and business development resources to support the growth of life sciences in Florida, giving the ecosystem the opportunity to retain companies rather than losing them to other communities,” said Abhinav Akhoury, vice president, corporate accounts, Thermo Fisher Scientific. “Through our sponsorship, Momentum Labs has the ability to provide the latest innovative technologies to high-growth life science companies that are developing tomorrow’s life-changing medicines.”

The North Central region of Florida is one of the largest biotech clusters in the state, home to over 100 life sciences companies and supporting around 1,200 jobs. Despite this established footing, there is a lack of flexible growth space, making it difficult for emerging companies to succeed. Momentum Labs will be the first space of its type in the region, providing growing life science companies with the ability to scale without having to move to other markets.

Companies that receive support from incubator programs are 87% more likely to survive after five years. Upon graduation, 84% of those companies stay in the communities where they received their support and funding. In partnership with Thermo Fisher, members of Momentum Labs will have access to innovative life science instruments and state-of-the-art lab equipment, infrastructure and resources within the region to support their growth.

“It’s challenging for growing companies to stay ahead of their space needs,” said Brian Crawford, chief executive officer at Concept Companies. “Not only is there a large expense for all the equipment needed, but there are also often extraordinary lead times associated with the acquisition and installation. Partnering with Thermo Fisher Scientific gives us the ability to offer the latest innovative instrumentation and equipment to our members allowing them to leverage their capital for growth.”

“By developing a purpose-built facility for emerging science in the Gainesville community, Momentum Labs is providing critical lab space, access to quality equipment, instrumentation and services, and tailored business development support these companies need for continued exponential growth,” said Kyla Frye, director of science and technology ecosystems and lead for Momentum Labs. “This ultimately helps us retain growing life sciences companies and their talent in the region while giving them the vital resources to advance their therapies from research to the clinic.”

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com

#     #     #

Email editor@

alachuatoday.com

• A 2021 study showed that breast milk of lactating mothers vaccinated against COVID-19 contained a significant supply of antibodies that may help protect nursing infants from the illness.
• A new follow-up study found these antibodies in the stool of infants who consumed the breast milk of vaccinated mothers.
• These findings are another piece of evidence suggesting that the breast milk of those vaccinated against COVID-19 may help protect babies from the illness.

GAINESVILLE, Fla., J an. 12, 2023 ‒ A new study from the University of Florida provides more evidence that the breast milk of people vaccinated against COVID-19 provides protection to infants too young to receive the vaccine.

This latest study follows up on findings published in 2021 showing that the breast milk of vaccinated people contained antibodies against SARS-CoV-2, the virus that causes COVID-19. The new study, published in the Journal of Perinatology, analyzed the stool of infants that consumed this breast milk and found SARS-CoV-2 antibodies there as well.

“Our first study showed there were SARS-CoV-2 antibodies in the breast milk, but we couldn’t say if those antibodies were getting through the babies’ gastrointestinal tract and possibly providing protection there,” said Joseph Larkin III, senior author of the study and an associate professor in the UF/IFAS department of microbiology and cell science.

Using a technique called a neutralization assay, the researchers showed that the antibodies found in the infants’ stool offered protection against the virus. The assay begins by isolating antibodies from the stool and adding them to a special line of cells that have the kind of receptors the SARS-CoV-2 virus uses to enter the cell. The researchers then introduce a SARS-CoV-2 pseudovirus, which acts like the virus that causes COVID-19 but is safer to use in the lab. The pseudovirus is fluorescent, so when it binds to a cell, the cell lights up.

“We saw that when the antibodies were present, there were fewer fluorescent cells compared to our controls where no antibodies were present,” said Lauren Stafford, one of the study’s first authors and a UF/IFAS College of Agricultural and Life Sciences doctoral student in Larkin’s lab.

“The antibodies run interference and don’t let the virus get to the cells,” Larkin added.

While the virus that causes COVID-19 is often thought of as mainly affecting the lungs, it can also invade the gut, which is why finding antibodies there is significant, the researchers said.

“The antibodies ingested through breast milk may provide a protective coating in the infants’ mouths and gastrointestinal tract,” said Dr. Vivian Valcarce Luaces, the study’s other first author and a postdoctoral fellowship trainee in neonatology.

The study also measured and tested antibodies found in the mothers’ blood plasma and breast milk soon after vaccination and then again about six months later. The researchers found that the antibodies in the plasma and milk of vaccinated people were better able to neutralize the virus, though they also observed that antibody levels decreased at the six-month mark, which other vaccine studies have found as well.

Dr. Josef Neu, one of the study’s co-authors and a professor in the UF College of Medicine department of pediatrics, division of neonatology, said the first and second studies together give a more complete picture of how vaccinating against COVID-19 during pregnancy and breastfeeding may be protective for parent and child.

“In our research, we’re following the journey of the antibodies, from the time they are produced in mom after vaccination and now through the baby’s digestive system. The next question is whether those babies are less likely to get COVID-19,” Dr. Neu said.

The researchers say larger studies are needed to answer that question, as this latest study included 37 mothers and 25 infants, a relatively small number of participants.

However, this study adds to a growing body of research revealing how vaccination against COVID-19 during pregnancy and breastfeeding may protect newborns, the researchers say. Currently children under sixth months of age cannot receive the vaccine, so breast milk may be the only avenue for providing immunity.

The study was funded by grants from the Children’s Miracle Network and The Gerber Foundation.

The Centers for Disease Control and Prevention recommends COVID-19 vaccination for people who are pregnant, breastfeeding, trying to get pregnant or who may become pregnant in the future. According to the CDC, as of late November 2022, just over 70% of pregnant people in the United States had completed the primary series of COVID-19 vaccines, though only 14% had received the bivalent booster.

#     #     #

Email editor@

alachuatoday.com

GAINESVILLE, Fla.,Jan. 13, 2023 - Scientists have discovered a way to alter the chemical properties of fentanyl, offering a safer alternative to the powerful pain reliever.

Fentanyl is a synthetic opioid similar to morphine but up to 100 times more potent. According to the Centers for Disease Control and Prevention, it is among the most abused pain relievers in the U.S. and the leading cause of overdose deaths. More than 80,000 Americans died from an opioid overdose in 2021.

In a study published in the journal Nature, a team of scientists from the University of Florida, Washington University in St. Louis, the University of Southern California and Stanford University, report how they modified fentanyl’s chemical structure to maintain its pain-relieving properties while reducing harmful side effects.

“Fentanyl is one of the world’s most powerful, yet dangerous pain-relieving medications,” said study co-author Jay McLaughlin, Ph.D., a professor of pharmacodynamics in the UF College of Pharmacy, part of UF Health, the University of Florida’s academic health center. “A team of multidisciplinary scientists from some of the nation’s leading universities came together to gain a new understanding of how the opioid receptor works, and from that research, we sought to generate a new medication that will be a safer pain reliever.”

Pain-killing drugs like fentanyl and morphine bind to the mu-opioid receptor on nerve cells. The interaction triggers a series of responses — from beneficial pain relief to serious side effects like respiratory distress, sedation, addiction and even death.

By applying new insights into the receptor structure, researchers designed a medication that binds to the established site of activity on the outside of the mu-opioid receptor, while also engaging a binding site for sodium ions that exists deep within the receptor. McLaughlin described these receptor sites as switches that turn on and off to control the drug’s effect on the body. Researchers found that when the new drug interacts with both sites on the mu-opioid receptor, it maintains its painkilling effects while reducing harmful side effects.

“The newly designed fentanyl medication is engineered to work as a partial agonist, which are drugs that bind to and activate a receptor but only have partial efficacy,” McLaughlin said. “When the drug binds to the mu-opioid receptor site, the interaction triggers pain relief, but the engagement with the sodium ion essentially turns the receptor off before the adverse effects can occur.”

Susruta Majumdar, Ph.D., led a team of scientists at Washington University to design the new fentanyl drug. Other researchers provided computer modeling support and studied it in cell assays before animal studies began at the University of Florida. McLaughlin tested the altered fentanyl drug in mice and found it provided pain relief without causing respiratory depression or other opioid side effects.

“The more we can learn about how opioid receptors work, the closer we get to developing safer pain medicines,” McLaughlin said. “We can expand this research to target other receptors and see if similar results may improve medications for substance abuse, mood disorders and other health conditions.”

Other scientists contributing to the study included Nobel Prize winner Brian Kobilka, M.D., Ph.D., and Georgios Skiniotis, Ph.D., from Stanford University; Vsevolod Katritch, Ph.D., from the University of Southern California; and Tao Che, Ph.D., from Washington University.

#     #     #

Email editor@

alachuatoday.com